Progenity Stock

Progenity ROA

Delisted

The Return on Assets (ROA) of Progenity (PROG) as of Aug 14, 2026 is -227.32 %. In the previous year, Return on Assets (ROA) was -124.66 % — a change of 82.35% (lower).

ROA

-227.32 %

YoY

82.35%

Last updated:

In 2026, Progenity's return on assets (ROA) was -227.32 %, a 82.35% increase from the -124.66 % ROA in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Progenity Stock analysis

What does Progenity do? Progenity Inc. is an American company specializing in the development and marketing of diagnostic tests and genetic screening solutions. It was founded in 2012 and is headquartered in San Diego, California. Progenity is a leading provider of prenatal screening and diagnostic solutions. The company offers a wide range of tests that help expectant parents identify potential health risks for their unborn child. Progenity's prenatal screening palette includes tests for determining chromosomal abnormalities, genetic disorders, and other health risks. A major advantage of these tests is that they are non-invasive, meaning that no dangerous invasive procedures need to be performed. Another important division of Progenity focuses on gastrointestinal health, where the company offers various diagnostic tests to identify and treat gastrointestinal diseases early. This includes tests for detecting colon cancer as well as genetic tests that indicate an increased risk for familial colon cancer syndromes. Progenity also has a division that focuses on cardiovascular diseases. Here, they offer genetic tests, among other things, to determine the risk of heart disease. In addition, the company offers a wide range of diagnostic solutions for general health, such as tests for identifying infectious diseases like HIV or HPV. Progenity also offers its customers various screening and diagnostic tests tailored to specific target groups. This includes tests for women seeking fertility treatment, as well as tests aiming to identify specific hereditary diseases related to cancer or other conditions. To provide customers with the best possible solutions, Progenity utilizes state-of-the-art technologies and innovative methods. The company is a leader in the application of liquid biopsy tests, an innovative method for identifying cancer cells in the blood. For a long time, Progenity has worked closely with leading US health authorities and is accredited by CLIA, the Clinical Laboratory Improvement Amendments. This means that the company operates in accordance with established standards and best practices and can provide its customers with accurate and reliable diagnostic solutions. In recent years, Progenity has experienced an impressive growth rate and has become a recognized provider of diagnostic solutions with a wide range of tests covering various areas of health. The company is committed to providing customers with the best possible solutions to promote their health and well-being. Progenity is one of the most popular companies on Eulerpool.

ROA Details

Understanding Progenity's Return on Assets (ROA)

Progenity's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Progenity's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Progenity's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Progenity’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Progenity stock

Return on Assets (ROA) of Progenity is -227.32 % in 2026.

Return on Assets (ROA) of Progenity changed from -124.66 % to -227.32 %, representing a 82.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Progenity since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Progenity with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Progenity

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Progenity